Overview
Children often respond differently to medications approved for adults, and therefore pediatric trials are required and critically needed for new antibiotics in order to inform dosing, efficacy, and safety.
Use CTTI’s recommendations to design pediatric antibacterial trials that ensure adequate enrollment, decrease the burden on sites and families, understand special considerations for neonates, develop appropriate informed consent procedures, and increase engagement with healthcare providers.
Solutions
Search AllRecommendation Summary
Recommendations
Resources
Related Items
- Pediatric Antibacterial and Antifungal Trials From 2007 to 2017
- Facilitators and barriers to the successful implementation of pediatric antibacterial drug trials: Findings from CTTI’s survey of investigators
- Advancing Pediatric Antibacterial Drug Development: A Critical Need to Reinvent our Approach
- Perceived Barriers to Pediatrician and Family Practitioner Participation in Pediatric Clinical Trials: Findings from the Clinical Trials Transformation Initiative
- Parents’ perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative
- Clinical Trials Transformation Initiative Releases New Recommendations to Improve Studies of Antibacterial Drugs for Children
- Clinical Trials Transformation Initiative Releases New Recommendations to Improve Studies of Antibacterial Drugs for Children
- CTTI Recommendations from the Antibacterial Drug Development (ABDD) Peds Trial Project
- Pediatric Trials in Antibacterial Drug Development: Findings from the Clinical Trials Transformation Project
- Pediatric Trials in Antibacterial Drug Development: Findings from the Clinical Trials Transformation Project
- Improving Pediatric Trials in Antibacterial Drug Development | No Sick Child Left Behind
- Children Underrepresented in Drug Studies
News
- CTTI Study Shows More Efforts Are Needed to Stimulate Pediatric Antibacterial and Antifungal Drug TrialsIn an article recently published in Pediatrics, CTTI researchers assess the impact of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) on pediatric antibacterial and antifungal drug trials. The ...